$PRLD
Prelude Therapeutics Inc

2021 Q1 Form 10-K Financial Statement

#000156459021013330 Filed on March 16, 2021

View on sec.gov

Income Statement

Concept 2021 Q1 2020 2019 Q4
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $5.500M $10.59M $1.246M
YoY Change 176.5%
% of Gross Profit
Research & Development $16.47M $48.18M $8.849M
YoY Change 92.95% 98.43%
% of Gross Profit
Depreciation & Amortization $160.0K $542.0K $220.0K
YoY Change 21.21% 41.88%
% of Gross Profit
Operating Expenses $21.97M $58.76M $10.10M
YoY Change 125.6% 142.03%
Operating Profit -$21.97M -$58.76M
YoY Change 125.6% 109.05%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net $667.0K $1.834M $56.00K
YoY Change 195.13% 240.26%
Pretax Income -$21.30M -$56.93M -$10.04M
YoY Change 106.49%
Income Tax
% Of Pretax Income
Net Earnings -$21.30M -$56.93M -$10.04M
YoY Change 123.95% 106.49%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$472.1K -$4.562M -$2.351M
COMMON SHARES
Basic Shares Outstanding 46.59M
Diluted Shares Outstanding

Balance Sheet

Concept 2021 Q1 2020 2019 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $363.0M $218.3M
YoY Change 1055.03%
Cash & Equivalents $363.0M $218.3M $18.88M
Short-Term Investments
Other Short-Term Assets $2.000M $2.500M
YoY Change 92.31%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $365.0M $220.8M $20.22M
YoY Change 993.07%
LONG-TERM ASSETS
Property, Plant & Equipment $2.627M $2.500M
YoY Change 56.25%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $0.00 $300.0K
YoY Change
Total Long-Term Assets $4.813M $2.800M $1.647M
YoY Change 64.71%
TOTAL ASSETS
Total Short-Term Assets $365.0M $220.8M $20.22M
Total Long-Term Assets $4.813M $2.800M $1.647M
Total Assets $369.8M $223.6M $21.87M
YoY Change 921.0%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $4.842M $3.900M $1.974M
YoY Change 95.0%
Accrued Expenses $6.179M $7.000M $2.603M
YoY Change 204.35%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due $0.00
YoY Change -100.0%
Total Short-Term Liabilities $12.42M $11.40M $4.835M
YoY Change 137.5%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $800.0K $0.00 $5.000K
YoY Change
Total Long-Term Liabilities $800.0K $0.00 $5.000K
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $12.42M $11.40M $4.835M
Total Long-Term Liabilities $800.0K $0.00 $5.000K
Total Liabilities $13.26M $11.40M $4.840M
YoY Change 137.5%
SHAREHOLDERS EQUITY
Retained Earnings -$128.7M -$50.50M
YoY Change
Common Stock $485.3M $1.085M
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $356.6M $212.2M -$49.41M
YoY Change
Total Liabilities & Shareholders Equity $369.8M $223.6M $21.87M
YoY Change 921.0%

Cashflow Statement

Concept 2021 Q1 2020 2019 Q4
OPERATING ACTIVITIES
Net Income -$21.30M -$56.93M -$10.04M
YoY Change 123.95% 106.49%
Depreciation, Depletion And Amortization $160.0K $542.0K $220.0K
YoY Change 21.21% 41.88%
Cash From Operating Activities -$16.14M -$46.18M -$14.10M
YoY Change 62.72% 79.92%
INVESTING ACTIVITIES
Capital Expenditures $986.0K $621.0K -$640.0K
YoY Change 1132.5% -20.38%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$986.0K -$621.0K -$640.0K
YoY Change 1132.5% -20.38%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $161.4M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 161.8M 246.2M -120.0K
YoY Change 442.13% 728.24%
NET CHANGE
Cash From Operating Activities -16.14M -46.18M -14.10M
Cash From Investing Activities -986.0K -621.0K -640.0K
Cash From Financing Activities 161.8M 246.2M -120.0K
Net Change In Cash 144.7M 199.4M -14.86M
YoY Change 629.02% 5972.78%
FREE CASH FLOW
Cash From Operating Activities -$16.14M -$46.18M -$14.10M
Capital Expenditures $986.0K $621.0K -$640.0K
Free Cash Flow -$17.13M -$46.80M -$13.46M
YoY Change 71.27% 76.96%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2020 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2020 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2020 dei Document Annual Report
DocumentAnnualReport
true
CY2020 dei Entity File Number
EntityFileNumber
001-39527
CY2020 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2020 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2020 dei Security12b Title
Security12bTitle
Common Stock, par value $0.0001 per share
CY2020 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2020 dei Document Period End Date
DocumentPeriodEndDate
2020-12-31
CY2020 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2020
CY2020 dei Trading Symbol
TradingSymbol
PRLD
CY2020 dei Entity Registrant Name
EntityRegistrantName
Prelude Therapeutics Inc
CY2020 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2020 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2020 dei Entity Small Business
EntitySmallBusiness
true
CY2020 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2020 dei Entity Shell Company
EntityShellCompany
true
CY2020 dei Entity Ex Transition Period
EntityExTransitionPeriod
false
CY2020 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2020 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
81-1384762
CY2020 dei Entity Address Address Line1
EntityAddressAddressLine1
200 Powder Mill Road
CY2020 dei Entity Address City Or Town
EntityAddressCityOrTown
Wilmington
CY2020 dei Entity Address State Or Province
EntityAddressStateOrProvince
DE
CY2020 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
19803
CY2020 dei City Area Code
CityAreaCode
302
CY2020 dei Local Phone Number
LocalPhoneNumber
467-1280
CY2021Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
46585860
CY2020 dei Icfr Auditor Attestation Flag
IcfrAuditorAttestationFlag
false
CY2020Q4 us-gaap Assets
Assets
223590000
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
11375000
CY2020Q4 us-gaap Liabilities
Liabilities
11407000
CY2019 us-gaap Net Income Loss
NetIncomeLoss
-27570000
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-107426000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
212183000
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
223590000
CY2019 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
846000
CY2020 dei Document Transition Report
DocumentTransitionReport
false
CY2020 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2020 dei Entity Central Index Key
EntityCentralIndexKey
0001678660
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
218309000
CY2019Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
18879000
CY2019Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1345000
CY2019Q4 us-gaap Assets Current
AssetsCurrent
20224000
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2480000
CY2020Q4 prld Deferred Offering Costs Non Current
DeferredOfferingCostsNonCurrent
301000
CY2019Q4 us-gaap Assets
Assets
21871000
CY2019Q4 us-gaap Capital Lease Obligations Current
CapitalLeaseObligationsCurrent
258000
CY2020Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
3920000
CY2019Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1974000
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
7455000
CY2019Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2603000
CY2019Q4 us-gaap Liabilities Current
LiabilitiesCurrent
4835000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
-49412000
CY2019Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
21871000
CY2019Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
5000
CY2019Q4 us-gaap Liabilities
Liabilities
4840000
CY2019Q4 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
66443000
CY2020Q4 us-gaap Temporary Equity Par Or Stated Value Per Share
TemporaryEquityParOrStatedValuePerShare
0.0001
CY2020Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
32000
CY2019Q4 us-gaap Temporary Equity Par Or Stated Value Per Share
TemporaryEquityParOrStatedValuePerShare
0.0001
CY2020 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
48177000
CY2020Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
319605000
CY2019Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
1085000
CY2019Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-50497000
CY2020Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2019 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
24279000
CY2020 us-gaap Operating Income Loss
OperatingIncomeLoss
-58763000
CY2019 us-gaap Operating Income Loss
OperatingIncomeLoss
-28109000
CY2020 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
1834000
CY2019 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
539000
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-56929000
CY2020 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-4.56
CY2019 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-16.52
CY2020 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
12478463
CY2019 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
1668549
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
-22693000
CY2019 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
5000
CY2020 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
100000
CY2020 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
146211000
CY2020 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
166630000
CY2020 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
5583000
CY2019 prld Payments Of Offering Costs
PaymentsOfOfferingCosts
CY2020 prld Payments Of Offering Costs
PaymentsOfOfferingCosts
2538000
CY2020 us-gaap Profit Loss
ProfitLoss
-56929000
CY2019 us-gaap Profit Loss
ProfitLoss
-27570000
CY2020 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
542000
CY2019 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-780000
CY2019 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
382000
CY2020 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-11000
CY2019 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-10000
CY2020 us-gaap Share Based Compensation
ShareBasedCompensation
5583000
CY2019 us-gaap Share Based Compensation
ShareBasedCompensation
846000
CY2020 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1155000
CY2019 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1345000
CY2020 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
1157000
CY2019 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
546000
CY2020 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
4614000
CY2019 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
1466000
CY2020 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-46177000
CY2019 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-25665000
CY2020 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
621000
CY2019 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
780000
CY2020 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-621000
CY2020 us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
166630000
CY2020 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
12000
CY2020 us-gaap Repayments Of Long Term Capital Lease Obligations
RepaymentsOfLongTermCapitalLeaseObligations
258000
CY2019 us-gaap Repayments Of Long Term Capital Lease Obligations
RepaymentsOfLongTermCapitalLeaseObligations
124000
CY2020 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
100000
CY2019 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
5000
CY2020 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
246228000
CY2019 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
29729000
CY2020 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
199430000
CY2019 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
3284000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
18879000
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
15595000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
218309000
CY2020 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
765000
CY2019 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
66000
CY2020 prld Offering Costs In Accrued Expenses
OfferingCostsInAccruedExpenses
265000
CY2020 prld Offering Costs In Accounts Payable
OfferingCostsInAccountsPayable
24000
CY2019 us-gaap Capital Lease Obligations Incurred
CapitalLeaseObligationsIncurred
382000
CY2020 us-gaap Nature Of Operations
NatureOfOperations
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">1. Nature of Operations</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.26%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prelude Therapeutics Incorporated (the &#8220;Company&#8221;) was incorporated in Delaware on February&#160;5, 2016 and is a clinical-stage biotechnology company focused on discovering and developing new medicines targeting chromatin function to treat cancer and rare diseases. Since beginning operations, the Company has devoted substantially all its efforts to research and development, conducting preclinical and clinical studies, recruiting management and technical staff, administration, and raising capital.</p>
CY2019Q4 prld Accrued Research And Development Liabilities Current
AccruedResearchAndDevelopmentLiabilitiesCurrent
658000
CY2020Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
420000
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
6839091
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
951669
CY2019Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
314000
CY2020 prld Number Of Non Cancelable Operating Leases
NumberOfNonCancelableOperatingLeases
2
CY2020 us-gaap Use Of Estimates
UseOfEstimates
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:4.26%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Use of Estimates</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.26%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and contingent liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates.</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.26%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Estimates and assumptions are periodically reviewed and the effects of the revisions are reflected in the accompanying financial statements in the period they are determined to be necessary. Significant areas that require management&#8217;s estimates include the fair value of the Company&#8217;s common stock prior to the IPO, stock-based compensation assumptions, and accrued clinical trial expenses.</p>
CY2020 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:4.26%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Concentration of Credit Risk</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.26%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial instruments that potentially subject the Company to significant concentrations of credit risk consist of cash and cash equivalents. The Company maintains deposits in federally insured financial institutions in excess of federally insured limits. The Company has not experienced any losses in such accounts and believes it is not exposed to significant credit risk beyond the normal credit risk associated with commercial banking relationships.</p>
CY2019 prld Number Of Non Cancelable Operating Leases
NumberOfNonCancelableOperatingLeases
2
CY2020 us-gaap Operating Lease Expense
OperatingLeaseExpense
1200000
CY2019 us-gaap Operating Lease Expense
OperatingLeaseExpense
900000
CY2020Q4 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
1400000
CY2020Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
1400000
CY2019 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
22970056
CY2020Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
3563000
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
3242
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2269742
CY2019Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
2203000
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
4785630
CY2020Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
1083000
CY2019Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
556000
CY2020 us-gaap Depreciation And Amortization
DepreciationAndAmortization
500000
CY2019 us-gaap Depreciation And Amortization
DepreciationAndAmortization
400000
CY2020Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
3614000
CY2019Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1631000
CY2020Q4 prld Accrued Research And Development Liabilities Current
AccruedResearchAndDevelopmentLiabilitiesCurrent
3421000
CY2020Q3 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
0.8646
CY2020 us-gaap Property Plant And Equipment Depreciation Methods
PropertyPlantAndEquipmentDepreciationMethods
Depreciation expense is recognized using the straight-line method over the estimated useful life of the asset, ranging from 5-7 years
CY2020Q4 us-gaap Deferred Offering Costs
DeferredOfferingCosts
300000
CY2020 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
8053858
CY2020Q4 prld Lessee Operating Lease Liability Payments Due Year Three And Thereafter
LesseeOperatingLeaseLiabilityPaymentsDueYearThreeAndThereafter
0
CY2020 us-gaap Defined Contribution Plan Maximum Annual Contributions Per Employee Percent
DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent
1.00
CY2020 us-gaap Defined Contribution Plan Employer Matching Contribution Percent
DefinedContributionPlanEmployerMatchingContributionPercent
0.04
CY2020 prld Number Of Equity Incentive Plans
NumberOfEquityIncentivePlans
2
CY2020 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
5583000
CY2019 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
846000
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
588961
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1703692
CY2019 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
19669
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
1.11
CY2019 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
1.84
CY2019 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
1.16
CY2019 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
1.02
CY2020 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
100545
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
115736
CY2020Q4 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Outstanding Options
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
6839091
CY2020 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0.99
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
1.66
CY2020 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
11.35
CY2020 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
1.37
CY2020 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P9Y2M1D
CY2020 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P8Y2M19D
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
431500000
CY2020Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
66300000
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
8.46
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
1.85
CY2018 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P9Y4M6D
CY2019 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P9Y2M12D
CY2020Q4 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Exercisable Options
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
951669
CY2020Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
28283000
CY2019Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
13659000
CY2020Q4 us-gaap Deferred Tax Assets In Process Research And Development
DeferredTaxAssetsInProcessResearchAndDevelopment
4753000
CY2019Q4 us-gaap Deferred Tax Assets In Process Research And Development
DeferredTaxAssetsInProcessResearchAndDevelopment
2216000
CY2020Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
33000
CY2020Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
33069000
CY2019Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
15875000
CY2020Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
32899000
CY2019Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
15409000
CY2020Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
170000
CY2019Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
466000
CY2019Q4 prld Deferred Tax Liabilities Stock Based Compensation
DeferredTaxLiabilitiesStockBasedCompensation
399000
CY2020Q4 prld Deferred Tax Liabilities Depreciation
DeferredTaxLiabilitiesDepreciation
170000
CY2019Q4 prld Deferred Tax Liabilities Depreciation
DeferredTaxLiabilitiesDepreciation
67000
CY2020Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
170000
CY2019Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
466000
CY2020Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
0
CY2019Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
0
CY2020 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
17500000
CY2019 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
9200000
CY2020 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.210
CY2019 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.210
CY2020 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.065
CY2019 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.069
CY2019 prld Effective Income Tax Rate Reconciliation Return To Provision
EffectiveIncomeTaxRateReconciliationReturnToProvision
0.007
CY2020 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
-0.012
CY2019 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
-0.004
CY2020 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Research
EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
0.044
CY2019 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Research
EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
0.054
CY2020 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.307
CY2019 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.336
CY2020 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.00
CY2019 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.00
CY2020 us-gaap Tax Credit Carryforward Description
TaxCreditCarryforwardDescription
The NOL and tax credit carryforwards are subject to review and possible adjustment by the Internal Revenue Service and state tax authorities. NOL and tax credit carryforwards may become subject to an annual limitation in the event of certain cumulative changes in the ownership interest of significant stockholders over a three year period in excess of 50%, as defined under Sections 382 and 383 of the Internal Revenue Code, respectively, as well as similar state provisions.
CY2020Q4 us-gaap Unrecognized Tax Benefits Interest On Income Taxes Accrued
UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued
0
CY2020Q4 us-gaap Unrecognized Tax Benefits Income Tax Penalties Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAccrued
0
CY2020 us-gaap Unrecognized Tax Benefits Interest On Income Taxes Expense
UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense
0
CY2020 us-gaap Unrecognized Tax Benefits Income Tax Penalties Expense
UnrecognizedTaxBenefitsIncomeTaxPenaltiesExpense
0
CY2020 us-gaap Income Tax Examination Year Under Examination
IncomeTaxExaminationYearUnderExamination
2016 2017 2018 2019

Files In Submission

Name View Source Status
0001564590-21-013330-index-headers.html Edgar Link pending
0001564590-21-013330-index.html Edgar Link pending
0001564590-21-013330.txt Edgar Link pending
0001564590-21-013330-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
gztchspvifgz000001.jpg Edgar Link pending
gztchspvifgz000002.jpg Edgar Link pending
gztchspvifgz000003.jpg Edgar Link pending
gztchspvifgz000004.jpg Edgar Link pending
gztchspvifgz000005.jpg Edgar Link pending
gztchspvifgz000006.jpg Edgar Link pending
gztchspvifgz000007.jpg Edgar Link pending
gztchspvifgz000008.jpg Edgar Link pending
gztchspvifgz000009.jpg Edgar Link pending
gztchspvifgz000010.jpg Edgar Link pending
gztchspvifgz000011.jpg Edgar Link pending
gztchspvifgz000012.jpg Edgar Link pending
gztchspvifgz000013.jpg Edgar Link pending
gztchspvifgz000014.jpg Edgar Link pending
gztchspvifgz000015.jpg Edgar Link pending
gztchspvifgz000016.jpg Edgar Link pending
gztchspvifgz000017.jpg Edgar Link pending
gztchspvifgz000018.jpg Edgar Link pending
gztchspvifgz000019.jpg Edgar Link pending
gztchspvifgz000020.jpg Edgar Link pending
gztchspvifgz000021.jpg Edgar Link pending
gztchspvifgz000022.jpg Edgar Link pending
gztchspvifgz000023.jpg Edgar Link pending
gztchspvifgz000024.jpg Edgar Link pending
gztchspvifgz000025.jpg Edgar Link pending
gztchspvifgz000026.jpg Edgar Link pending
gztchspvifgz000027.jpg Edgar Link pending
gztchspvifgz000028.jpg Edgar Link pending
gztchspvifgz000029.jpg Edgar Link pending
gztchspvifgz000030.jpg Edgar Link pending
gztchspvifgz000031.jpg Edgar Link pending
gztchspvifgz000032.jpg Edgar Link pending
prld-10k_20201231.htm Edgar Link pending
prld-20201231.xml Edgar Link completed
prld-20201231.xsd Edgar Link pending
prld-20201231_cal.xml Edgar Link unprocessable
prld-20201231_def.xml Edgar Link unprocessable
prld-20201231_lab.xml Edgar Link unprocessable
prld-20201231_pre.xml Edgar Link unprocessable
prld-ex231_598.htm Edgar Link pending
prld-ex311_9.htm Edgar Link pending
prld-ex312_8.htm Edgar Link pending
prld-ex321_6.htm Edgar Link pending
prld-ex322_7.htm Edgar Link pending
prld-ex44_599.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending